A pilot study of two new imaging scans after high precision radiation therapy for patients with limited secondary spread of cancer to the lung.

Not Applicable

Completed

• Conditions: Metastatic cancer to the lung; Cancer - Other cancer types

• Registration Number: ACTRN12613000746730
• Lead Sponsor: Peter MacCallum Cancer Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-07-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

One or two metastases within the lung parenchyma.
Patients with primary cancers of epithelial, sarcomatoid or germ cell histologies who are treated with curative intent.
Aged 18 years or older.
ECOG performance of 0-2 inclusive.
The tumour must have a peripheral location, defined as at least 1cm beyond the mediastinum and beyond the bifurcation of the lobar bronchi.
Maximal tumour diameter < 5cm.
No known extrathoracic disease prior to enrollment. Primary is controlled.
Patient has provided written informed consent for participation in this trial prior to any protocol specific procedures.
Patient must be medically inoperable, have technically high risk disease for surgery or refuse surgery.

Exclusion Criteria

Previous high-dose thoracic radiotherapy.
Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are not excluded (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotrophin releasing hormone receptor modulators).
Any patient who is currently pregnant or breastfeeding.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To measure the accrual rate in order to assess the potential of escalation to larger studies [1 year after last patient treated on protocol]